In addition, from a clinical point of view, as metformin, an antidiabetic drug associated with a reduction in PCa risk 71, 72, has been shown to reduce insulin levels and insulin resistance, the results presented herein could invite to suggest that one of the putative mechanisms that might help to explain the beneficial actions of metformin on PCa development and progression might be the reduction in insulin resistance at the PG level. This evidence concerns the gene INS and Insulin resistance.